CELYAD SA/ADR (NASDAQ:CYAD) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Tuesday, Zacks.com reports. The firm currently has a $14.00 target price on the stock. Zacks Investment Research‘s price target indicates a potential upside of 22.48% from the company’s previous close.
According to Zacks, “Celyad SA is a biopharmaceutical company. The Company develops and commercializes cell based regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. Celyad SA is based in Mont-Saint-Guibert, Belgium. “
CYAD has been the subject of a number of other research reports. ValuEngine upgraded shares of CELYAD SA/ADR from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Piper Jaffray Companies decreased their target price on shares of CELYAD SA/ADR from $41.00 to $25.00 and set an “overweight” rating for the company in a research report on Friday, July 5th. William Blair reiterated a “buy” rating on shares of CELYAD SA/ADR in a research report on Friday. Finally, HC Wainwright reiterated a “buy” rating and issued a $48.00 target price on shares of CELYAD SA/ADR in a research report on Monday. Five analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average price target of $29.00.
An institutional investor recently raised its position in CELYAD SA/ADR stock. Morgan Stanley raised its holdings in CELYAD SA/ADR (NASDAQ:CYAD) by 24.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,473 shares of the company’s stock after acquiring an additional 2,488 shares during the quarter. Morgan Stanley owned 0.13% of CELYAD SA/ADR worth $143,000 as of its most recent filing with the Securities and Exchange Commission. 7.28% of the stock is currently owned by hedge funds and other institutional investors.
CELYAD SA/ADR Company Profile
Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma.
Recommended Story: Mutual funds are not immune from market timing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CELYAD SA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELYAD SA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.